A dissimilar biosimilar? Lichenoid drug eruption induced by an infliximab biosimilar-Reference-Cited by-同舟云学术

A dissimilar biosimilar? Lichenoid drug eruption induced by an infliximab biosimilar

Published:2018-02-07 Issue:4 Volume:178 Page:965-968
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Gonzalez N.¹^ORCID,Patel P.²,Han G.¹

Affiliation:

1. Icahn School of Medicine at Mount Sinai, Dermatology 1425 Madison Avenue, Box 1047 New York NY 10029‐6574 U.S.A.

2. Albert Einstein College of Medicine Department of Medicine Division of Dermatology Montefiore Medical Center 1300 Morris Park Avenue Bronx NY 10461 U.S.A.

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.15686

Reference15 articles.

1. U.S. Food and Drug Administration.Information on biosimilars. Available at:https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/default.htm(last accessed 1 February 2018).

2. Lichen planus–like eruptions: An emerging side effect of tumor necrosis factor-α antagonists

3. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

4. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

5. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications;Journal of the European Academy of Dermatology and Venereology;2023-02-04

2. Lichenoid Drug Eruptions;Drug Eruptions;2022

3. The inflammation in cutaneous lichen planus is dominated by IFN‐ϒ and IL‐21—A basis for therapeutic JAK1 inhibition;Experimental Dermatology;2020-11-12

4. Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review;Acta Dermato Venereologica;2020

5. Reopening the case for case reports;British Journal of Dermatology;2020-01